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Triple-negative breast cancer is a particularly difficult to treat and biologically
aggressive disease with limited treatment options. However, a subset of patients
with triple-negative tumours may respond to chemotherapy. Therefore, optimisation
of chemotherapy regimens may be key in treating triple-negative breast cancer.
Emerging treatment approaches include novel chemotherapeutic agents such as the
epothilones. The epothilones are a group of novel microtubule-stabilising agents
with demonstrated activity in anthracycline-/taxane-resistant triple-negative breast
cancer, and ongoing trials are evaluating the combination of epothilones with
targeted agents or inclusion of epothilones in novel combination regimens. Other
interesting new treatment options include the PARP inhibitors, which are currently
in clinical trials for triple-negative breast cancer.
© 2009 Elsevier Ltd. All rights reserved.
1. Introduction
Hormone receptor (oestrogen and progesterone) and
human epidermal growth factor receptor 2 (HER2)
status identify key molecular subtypes of human breast
tumours and currently guide choice of therapy.
For patients with hormone-receptor positivemetastatic
breast cancer (MBC), hormone therapy with tamoxifen,
fulvestrant, and aromatase inhibitors (anastrozole, letro-
zole, exemestane in postmenopausal patients) or ovarian
suppression (in premenopausal patients) represent the
backbone of treatment, with or without additional
chemotherapy. For patients with HER2-positive breast
cancer, regardless of any other characteristics, the in-
troduction of anti-HER2 targeted agents has dramatically
improved prognosis. 1
Triple-negative breast cancer lacks overexpression of
all three receptors (oestrogen, progesterone and HER2),
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and represents ~15% of all breast cancers. Triple-negative
disease is characterised by a high proliferation rate, high
risk of early recurrence and a high incidence of visceral
and CNS metastases. 2,3 For this particularly aggressive
subset of breast cancer, effective treatment choices are
currently limited to chemotherapy; no targeted agents
have been developed specifically for triple-negative can-
cer. For instance, in the neoadjuvant setting, a significant
proportion of triple-negative tumours achieve a patho-
logical complete response (pCR) with chemotherapy. It is
important to note that the prognosis for triple-negative
patients who achieve a pCR with chemotherapy in the
neoadjuvant setting is similar to that for other breast
cancer phenotypes. 4 In contrast, patients with triple-
negative breast cancer who fail to achieve a pCR have
a worse prognosis. 5 It is therefore important to offer
these patients the most effective treatments as early as
possible in their disease course, and to identify predictive
and prognostic markers to guide treatment choice.
Treatment options for patients in whom disease
recurs vary according to key patient- and disease-
related factors. These include age, site and extent of
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metastases, treatment-free interval, and prior adjuvant
chemotherapy. Due to the high risk of relapse and lack of
other therapeutic options, the majority of triple-negative
breast cancer patients receive adjuvant chemotherapy.
This typically includes anthracyclines and/or taxanes.
Therefore, in case of relapse, treatment options are
further limited by the prior exposure to therapy and
the resulting emergent treatment resistance. In recent
years, a number of new treatment options have emerged
for patients with triple-negative disease. These include
a novel group of cytotoxic agents, the epothilones, as
well as agents withmolecular targets.This article reviews
the latest developments for treating patients with triple-
negative breast cancer.
2. Combination chemotherapy in triple-negative
disease
Although combination chemotherapy is routinely used
in the adjuvant setting, its use for treating MBC is more
controversial. 6 Clinical studies have shown that combi-
nation therapy offers only a limited survival advantage
compared with single-agent therapy or sequential mono-
therapy. 7−10 An additional consideration for selecting
combination therapy is whether the efficacy benefits
associated with combining treatment options outweigh
the risks of additive drug side effects. Consequently,
the disadvantage of increased toxicity and diminished
quality of life during treatment have generally been
regarded as sufficient to negate the minimal benefit that
combination therapy might offer. 11
Nevertheless, data do suggest that combination
therapy may offer improved outcomes in terms of
progression-free survival (PFS). For example, a recent
study of vinorelbine plus gemcitabine vs vinorel-
bine alone demonstrated a significantly prolonged PFS
for the combination regimen (6.0 vs 4.0 months, hazard
ratio [HR] 0.66; 95% confidence interval [CI] 0.50−0.88;
P=0.0028). 12 Judicious selection of new combination
regimes using drugs with minimally overlapping resis-
tance and toxicity profiles may yield future progress.
Moreover, combination chemotherapy − as well as novel
combinations of cytotoxic and targeted agents − may
still be of particular clinical relevance for patients with
aggressive triple-negative disease given their extremely
poor prognosis, especially once their disease has
metastasised.
Novel agents that overcome the common mechanisms
of drug resistance and retain clinically relevant activity
in the treatment of metastatic disease are of particular
relevance in this subset of breast cancer patients.
The epothilones are a novel class of microtubule-
stabilising agents that are less susceptible to the
cellular mechanisms of resistance associated with other
chemotherapeutic drug classes. Among the epothilones,
Fig. 1 – Efficacy of ixabepilone monotherapy in triple-
negative breast cancer: a subgroup analysis from phase II
trials. 13
ixabepilone (BMS-247550) is themost advanced in clinical
development. Indeed, ixabepilone has received approval
from the US Food and Drug Administration for the
treatment of metastatic or locally advanced breast cancer
after failure of an anthracycline and a taxane 14 and is
currently under regulatory review in Europe.
Clinical trials have shown that ixabepilone exhibits
potent antitumour effects in all stages of breast cancer,
from patients receiving neoadjuvant therapy to those
with heavily pre-treated MBC 15−19 (see also the paper
by Fumoleau in this supplement 20). In a sub-analysis of
data from five clinical trials, Pivot and colleagues 13 found
that ixabepilone also demonstrated notable antitumour
activity in patients with triple-negative breast cancer. 15,16
Interestingly, in the neoadjuvant setting, a greater
proportion of patients with triple-negative disease
achieved a pCR with ixabepilone (breast plus nodes;
pCR=19%) compared with those with hormone receptor
positive disease (pCR=8%). This finding was consistent
with a report by Liedtke and colleagues for taxanes. 21
Generally, across the phase II ixabepilone clinical trial
program, patients with triple-negative disease achieved
overall response rates comparable to those of patients
without triple-negative disease (Fig. 1). Median PFS in
the phase II trials of ixabepilone given as single-agent
therapy ranged from 2.5 to 5.7 months for those without
triple-negative disease and from 1.6 to 4.6 months for
those with triple-negative disease. 13
The efficacy and safety of ixabepilone in combination
with capecitabine for MBC has also been investigated
in two phase III trials (CA163046 and CA163048). In
the pivotal study (046), patients were prospectively
defined with a strict definition of resistance to previous
anthracycline and taxane therapy, 19 whereas in the
second, confirmatory study (048) patients were pre-
treated or resistant to an anthracycline and a taxane. 22
In study 046, the overall response rate assessed by
independent radiology review was 35% for patients who
received combination therapy compared with 14% for
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Fig. 2 – Overall response rates among patients treated with
ixabepilone + capecitabine or capecitabine alone: overall
and subgroup analyses. 23
those treated with capecitabine alone (P=0.0001). 19
Investigator-assessed responses were 42% and 23%,
respectively. Consistent with this, the investigator-
assessed overall response rate in study 048 was
42% in the ixabepilone combination therapy arm and
23% for capecitabine alone. 22 Across these two studies,
ixabepilone in combination with capecitabine offered an
increase in PFS of approximately 40% compared with
capecitabine alone. When outcomes for the subgroup of
patients with triple-negative disease who took part in
study 046 were evaluated, the results were consistent
with the overall findings. PFS was prolonged in patients
with triple-negative disease from 2.1 months among
those who received capecitabine alone to 4.1 months
among those treated with ixabepilone plus capecitabine,
indicating a 32% reduction in the risk of progressive
disease compared with capecitabine alone. 23 Moreover,
there was a three-fold increase in the overall response
rate in patients with triple-negative disease, from
9% among those who received capecitabine alone
to 27% among those treated with the combination
regimen (Fig. 2).
3. Novel molecular targets in triple-negative
disease
Targeted agents have also been investigated in triple-
negative patient populations. For example, clinical
trials of bevacizumab in combination with either
paclitaxel or docetaxel as first-line therapy for patients
with metastatic or locally advanced breast cancer
demonstrated that combination treatment significantly
increased both the objective response rate and the
median PFS compared with monotherapy. 24,25 Miller and
coworkers (2007) reported a significant improvement
in the overall response rate with paclitaxel plus
bevacizumab as first-line therapy for MBC (36.9% vs
21.2% for paclitaxel alone; P=0.0001). In this study,
patients also experienced a statistically significant
improvement in PFS with combined paclitaxel plus
bevacizumab compared with paclitaxel alone (11.8 vs
5.9 months, P<0.001) but no significant improvement
in overall survival (26.2 vs 25.2 months). In particular,
the addition of bevacizumab to paclitaxel resulted in
a similar PFS benefit in both the triple-negative and
hormone receptor positive groups (HR 0.53 and 0.54,
respectively). Similarly, significant improvements in both
overall response rate and PFS have been reported for the
combination of docetaxel and bevacizumab compared
with docetaxel alone as first-line therapy for locally
advanced or metastatic breast cancer. 25 In this case,
there was a trend towards improved 1-year survival with
combination therapy. Again, the subgroup analysis has
highlighted a similar benefit for patients with triple-
negative breast cancer.
A variety of alternative rational molecular targets
for the treatment of patients whose disease is HER2-
negative, including those with triple-negative disease,
has emerged in recent years. 26
Triple-negative tumours have many histological sim-
ilarities to the subgroup of breast tumours that carry
a mutation in the Breast Cancer 1 (BRCA-1) gene. The
BRCA1 gene product acts as a tumour suppressor by
maintaining genomic integrity via DNA damage repair,
ubiquitination and transcriptional regulation. 27 Loss
of functional BRCA1 results in the accumulation of
genetic mutations, genomic instability and a predis-
position towards oncogenic transformation. Such cells
depend on base excision repair (BER) mechanisms to
rectify endogenous DNA damage and poly(ADP-ribose)
polymerase (PARP) enzyme is a critical component of
BER. PARP inhibition has been shown to be effective
in killing BRCA-1-mutant cell lines, including breast
cancer cell lines, 28 and such inhibitors may sensitise
cancer cells to DNA-damaging agents. 29 PARP inhibitors
including AZD2281 in combination with paclitaxel
(study code: NCT00707707) or as monotherapy (study
code: NCT00679783), and BSI-201 in combination with
carboplatin plus gemcitabine (study code: NCT00540358),
are currently in early clinical development and their
potential in the treatment of triple-negative MBC awaits
further clinical evaluation.
Other potential molecular targets for patients with
triple-negative disease are also under investigation.
For example, between 50% and 70% of triple-negative
tumours have been shown to overexpress the epidermal
growth factor receptor (EGFR), around 31% overexpress
the c-Kit receptor which on binding of stem cell factor
initiates a signalling cascade that is thought to promote
cell survival, proliferation and migration, and over-
expression of src (a tyrosine kinase involved in growth
cellular signal propagation) has also been reported in
triple-negative breast tumours. 26 These observations
provide a rational basis for the evaluation of EGFR-
targeted agents such as cetuximab and erlotinib, c-Kit
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targeted agents such as imatinib and src-targeted agents
such as dasatinib in the treatment of triple-negative
breast cancer. Preliminary data with the EGFR inhibitor
cetuximab suggest that combination therapy with carbo-
platin may be effective in patients with triple-negative
disease. 30 Among a population of patients with stage IV,
triple-negative breast cancer,most of whom had received
prior treatment for metastatic disease, the response rate
for patients treated with cetuximab alone was low
with only 6% of patients responding. This improved to
17% when carboplatin was added on disease progression,
a rate that was comparable with a response rate of
17% observed for patients randomised to cetuximab plus
carboplatin throughout. However, while the improved
response rates appear to favour combination therapy, the
differences between treatment arms failed to reach sta-
tistical significance. In a subset analysis investigating the
effects of adding cetuximab to irinotecan and carboplatin
in 72 patients with triple-negative breast cancer, cetux-
imab increased the objective response rate from 30% to
49%. 31 However, the improvement in response rates
was not associated with any improvement in PFS
(irinotecan plus carboplatin 5.1 months vs 4.7 months
for irinotecan plus carboplatin plus cetuximab).
Given these results, a phase II study is now underway
to examine the efficacy of ixabepilone in combination
with cetuximab in patients with triple-negative locally
advanced or metastatic breast cancer (study code:
NCT00633464). Patients who have not received prior
chemotherapy in the metastatic setting with confirmed
triple-negative disease will be randomised to ixabepilone
only or ixabepilone in combination with cetuximab, and
will be followed until disease progression or withdrawal
for unacceptable toxicity. The primary endpoint of
the study will be the overall response rate, with
PFS, time to response and duration of response as
secondary study endpoints. Final results of this study are
expected in 2011.
4. Conclusions
Triple-negative MBC represents a considerable clinical
challenge. Although triple-negative tumours are more
likely to undergo early relapse and develop visceral
metastases, patients with this poor prognosis subtype
can achieve substantial benefits with chemotherapy.
However, treatment choices for patients with triple-
negative MBC are limited by often heavy pre-treatment
with the most effective chemotherapeutic agents.
Accordingly, there is a need for new agents that are
effective in triple-negative disease which can overcome
the resistance mechanisms that preclude the sustained
efficacy of the anthracyclines and taxanes in the
metastatic disease setting. The epothilones, notably
ixabepilone, the most developmentally advanced agent
in this group, are one such new group of cytotoxic
agents that retain activity in anthracycline- and taxane-
resistant breast cancer, and are emerging as a valuable
alternative for patients with MBC including triple-
negative disease.
The growing appreciation of the use of combination
chemotherapy with newer cytotoxics, with improved
efficacy and/or a more tolerable side-effect burden
compared with older agents and regimens, has opened
new potential treatment options particularly for those
with triple-negative disease. Such regimens are gaining
increasing acceptance in the management of late-stage
disease. Phase II studies have demonstrated the activity
of ixabepilone in the treatment of triple-negative disease
from early stage through to heavily pre-treated MBC,
and data from phase III studies support combination
chemotherapy with ixabepilone and capecitabine with
indications of both improved response and prolonged
progression-free intervals.
Novel molecular targets in triple-negative breast
cancer are also emerging and providing a rationale
for the evaluation of a number of novel combination
regimens in triple-negative breast cancer. Again, there
is early evidence of improved response rates and it
is hoped that ongoing studies with regimens such as
that of ixabepilone in combination with cetuximab may
prove effective in extending progression-free periods for
patients with triple-negative MBC.
Patients with metastatic triple-negative breast cancer
face a bleak prognosis. However, with the emergence
of novel chemotherapeutics, evidence of efficacy and
tolerability of novel combination regimens and the incor-
poration of novel targeted agents into chemotherapeutic
regimens, there remains hope for improved outcomes for
this vulnerable and under-served group of patients.
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